4-(N-methyl-N-phenylamino)-8-(1-methylethyl)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine | 1099104-60-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(N-methyl-N-phenylamino)-8-(1-methylethyl)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine
• 英文别名: 8-(1-methylethyl)-4-(N-methyl-N-phenylamino)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine；8-isopropyl-4-(N-methyl-N-phenylamino)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine；(8-Isopropyl-2-methylsulfanyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-methyl-phenyl-amine；N-methyl-2-methylsulfanyl-N-phenyl-8-propan-2-ylpyrazolo[1,5-a][1,3,5]triazin-4-amine
• CAS: 1099104-60-5
• 化学式: C₁₆H₁₉N₅S
• 分子量: 313.426
• InChiKey: SFOGORRSEIHICL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  71.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(N-methyl-N-phenylamino)-8-(1-methylethyl)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine 在 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 27.0h， 生成 8-isopropyl-2-(methylsulfonyl)-4-[N-(4-phenyl)benzylamino]pyrazolo[1,5-a]-1,3,5-triazine
  参考文献：
  名称：

  PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF

  摘要：

  化合物的化学式（I）或其药用可接受的盐，其中R1是（C1-C6）烷基或（C3-C6）环烷基；R2是（C1-C6）烷基，（C3-C6）环烷基，（C1-C6）烯基，（C1-C6）氟烷基，（C1-C3）氟烷氧基或（C1-C6）烷氧（C1-C6）烷基，取代：（i）具有一到三个羟基，或（ii）具有NRaRb基团，其中Ra和Rb独立地是氢原子或（C1-C3）烷基；或者取代有一到三个羟基的吡咯甲基基团；R9与R2或氢相同；R2和R9基团可独立地被取代为—OCOR3基团，其中R3是天然或非天然氨基酸衍生物或哌啶基团；或者，R2和R9共同形成一个杂环化合物；X和Y是可独立取代的苯基或杂芳基，杂芳基是噻吩基，吡啶基，嘧啶基，噻唑基，吡咯基或呋喃基；R6是氢或（C1-C3）烷基。

  公开号：

  US20120184557A1
• 作为产物：
  描述：

  在 sodium tetrahydroborate 、 三氟乙酸 、 sodium hydroxide 、 水 作用下， 以 二氯甲烷 为溶剂， 以241 mg的产率得到4-(N-methyl-N-phenylamino)-8-(1-methylethyl)-2-(methylsulfanyl)pyrazolo[1,5-a]-1,3,5-triazine
  参考文献：
  名称：

  吡唑并[1,5 - a ] -1,3,5-三嗪肌球蛋白衍生物的合成及抗增殖评价

  摘要：

  吡唑并[1,5-一个] -1,3,5-三嗪衍生物myoseverin 1A-1C是从4-（制备Ñ甲基ñ -苯基氨基）-2- methylsulfanylpyrazolo [1,5-一个] -1,3- ，5-三嗪2。他们的细胞毒性活性，微管蛋白聚合的抑制作用和细胞周期的影响进行了评估。化合物1a和1c是有效的微管蛋白抑制剂，在大摩尔浓度下，在大肠癌细胞系中显示出特定的抗增殖活性。

  DOI：

  10.1016/j.bmc.2009.03.007

文献信息

• Pyrazolo[1,5-a]-1,3,5-triazine derivatives, preparation thereof, and therapeutic use thereof
  申请人：Meijer Laurent

  公开号：US08691982B2

  公开（公告）日：2014-04-08

  A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R1 is a (C1-C6)alkyl or (C3-C6)cycloalkyl group; R2 is a (C1-C6)alkyl, (C3-C6)cycloalkyl, (C1-C6)alkenyl, (C1-C6)fluoroalkyl, (C1-C3)fluoroalkoxy, or (C1-C6)alkoxy(C1-C6)alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NRaRb group, where Ra and Rb are independently a hydrogen atom or a (C1-C3)alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R9 is the same as R2 or hydrogen; the R2 and R9 groups independently being substitutable with an —OCOR3 group, where R3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R2 and R9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R6 is a hydrogen or a (C1-C3)alkyl group.

  化合物式（I）或其药学上可接受的盐，其中R1是（C1-C6）烷基或（C3-C6）环烷基；R2是（C1-C6）烷基，（C3-C6）环烷基，（C1-C6）烯基，（C1-C6）氟烷基，（C1-C3）氟烷氧基或（C1-C6）烷氧（C1-C6）烷基，被取代：（i）一个到三个羟基，或（ii）一个NRaRb基团，其中Ra和Rb分别是氢原子或（C1-C3）烷基；或一个带有一个到三个羟基的吡咯烷甲基基团；R9与R2相同或为氢；R2和R9基团各自可被取代为—OCOR3基团，其中R3是天然或非天然氨基酸衍生物或哌啶基团；或者，R2和R9共同形成一个杂环化合物；X和Y分别是可取代的苯基或杂环芳基基团，其中杂环芳基基团是噻吩基，吡啶基，嘧啶基，噻唑基，吡咯基或呋喃基；R6是氢或（C1-C3）烷基基团。
• Pyrazolo[1,5-<i>a</i>]-1,3,5-triazine as a Purine Bioisostere: Access to Potent Cyclin-Dependent Kinase Inhibitor (<i>R</i>)-Roscovitine Analogue
  作者：Florence Popowycz、Guy Fournet、Cédric Schneider、Karima Bettayeb、Yoan Ferandin、Cyrile Lamigeon、Oscar M. Tirado、Silvia Mateo-Lozano、Vicente Notario、Pierre Colas、Philippe Bernard、Laurent Meijer、Benoît Joseph

  DOI：10.1021/jm801340z

  日期：2009.2.12

  Pharmacological inhibitors of cyclin-dependent kinases (CDKs) have a wide therapeutic potential. Among the CDK inhibitors currently under clinical trials, the 2,6,9-trisubstituted purine (R)-roscovitine displays rather high selectivity, low toxicity, and promising antitumor activity. In an effort to improve this structure, we synthesized several bioisosteres of roscovitine. Surprisingly, one of them, pyrazolo[1,5-a]-1,3,5-triazine 7a (N-&-N1, GP0210), displayed significantly higher potency, compared to (R)-roscovitine and imidazo[2,1-f]-1,2,4-triazine 13 (N-&-N2, GP0212), at inhibiting various CDKs and at inducing cell death in a wide variety of human tumor cell lines. This approach may thus provide second generation analogues with enhanced biomedical potential.
• DERIVÉS DE PYRAZOLO[1,5-A]-1,3,5-TRIAZINES, LEUR PREPARATION ET LEUR APPLICATION EN THÉRAPEUTIQUE
  申请人：Centre National de la Recherche Scientifique (C.N.R.S.)

  公开号：EP2406263B1

  公开（公告）日：2013-09-25
• PYRAZOLO[1,5-A]-1,3,5-TRIAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
  申请人：Meijer Laurent

  公开号：US20120184557A1

  公开（公告）日：2012-07-19

  A compound of formula (I), or a pharmaceutically acceptable salt thereof, where R 1 is a (C 1 -C 6 )alkyl or (C 3 -C 6 )cycloalkyl group; R 2 is a (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 6 )alkenyl, (C 1 -C 6 )fluoroalkyl, (C 1 -C 3 )fluoroalkoxy, or (C 1 -C 6 )alkoxy(C 1 -C 6 )alkyl group, substituted: (i) with one to three hydroxyl groups, or (ii) with an NR a R b group, where R a and R b are independently a hydrogen atom or a (C 1 -C 3 )alkyl group; or a pyrrolidinylmethyl group substituted with one to three hydroxyl groups; R 9 is the same as R 2 or hydrogen; the R 2 and R 9 groups independently being substitutable with an —OCOR 3 group, where R 3 is a natural or unnatural amino acid derivative or a piperidyl group; alternatively, R 2 and R 9 together form a heterocyclic compound; X and Y are independently a substitutable phenyl or heteroaryl group, the heteroaryl group being a thienyl, pyridyl, pyrimidinyl, thiazolyl, pyrrolyl, or furanyl group; and R 6 is a hydrogen or a (C 1 -C 3 )alkyl group.

  化合物的化学式（I）或其药用可接受的盐，其中R1是（C1-C6）烷基或（C3-C6）环烷基；R2是（C1-C6）烷基，（C3-C6）环烷基，（C1-C6）烯基，（C1-C6）氟烷基，（C1-C3）氟烷氧基或（C1-C6）烷氧（C1-C6）烷基，取代：（i）具有一到三个羟基，或（ii）具有NRaRb基团，其中Ra和Rb独立地是氢原子或（C1-C3）烷基；或者取代有一到三个羟基的吡咯甲基基团；R9与R2或氢相同；R2和R9基团可独立地被取代为—OCOR3基团，其中R3是天然或非天然氨基酸衍生物或哌啶基团；或者，R2和R9共同形成一个杂环化合物；X和Y是可独立取代的苯基或杂芳基，杂芳基是噻吩基，吡啶基，嘧啶基，噻唑基，吡咯基或呋喃基；R6是氢或（C1-C3）烷基。
• Synthesis and antiproliferative evaluation of pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives
  作者：Florence Popowycz、Cédric Schneider、Salvatore DeBonis、Dimitrios A. Skoufias、Frank Kozielski、Carlos M. Galmarini、Benoît Joseph

  DOI：10.1016/j.bmc.2009.03.007

  日期：2009.5

  Pyrazolo[1,5-a]-1,3,5-triazine myoseverin derivatives 1a–c were prepared from 4-(N-methyl-N-phenylamino)-2-methylsulfanylpyrazolo[1,5-a]-1,3,5-triazine 2. Their cytotoxic activity, inhibition of tubulin polymerization, and cell cycle effects were evaluated. Compounds 1a and 1c are potent tubulin inhibitors and displayed specific antiproliferative activity in colorectal cancer cell lines at micromolar

  吡唑并[1,5-一个] -1,3,5-三嗪衍生物myoseverin 1A-1C是从4-（制备Ñ甲基ñ -苯基氨基）-2- methylsulfanylpyrazolo [1,5-一个] -1,3- ，5-三嗪2。他们的细胞毒性活性，微管蛋白聚合的抑制作用和细胞周期的影响进行了评估。化合物1a和1c是有效的微管蛋白抑制剂，在大摩尔浓度下，在大肠癌细胞系中显示出特定的抗增殖活性。